Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.71 |
| ▸ | MAPT | P10636 | 11/20 | 0.71 |
| ▸ | RECQL | P46063 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 4/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.68 |
| ▸ | LMNA | P02545 | 4/20 | 0.68 |
| ▸ | HTR6 | P50406 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1844111 | 0.92 | MAPT (0.80) | ALDH1A1MAPTRECQLHTTNPSR1 | |
| SCHEMBL1849593 | 0.91 | ALDH1A1 (0.73) | ALDH1A1MAPTRECQLHTTNPSR1 | |
| SCHEMBL1842808 | 0.90 | ALDH1A1 (0.71) | ALDH1A1MAPTRECQLHTTNPSR1 | |
| SCHEMBL1847634 | 0.90 | ALDH1A1 (0.71) | ALDH1A1MAPTRECQLHTTNPSR1 | |
| SCHEMBL1843885 | 0.90 | ALDH1A1 (0.71) | ALDH1A1MAPTRECQLHTTNPSR1 | |
| SCHEMBL1844856 | 0.88 | MAPT (0.75) | ALDH1A1MAPTRECQLHTTNPSR1 | |
| SCHEMBL2388607 | 0.88 | ALDH1A1 (0.69) | ALDH1A1MAPTRECQLHTTNPSR1 | |
| SCHEMBL1841806 | 0.86 | ALDH1A1 (0.75) | ALDH1A1MAPTRECQLHTTNPSR1 | |
| SCHEMBL1846950 | 0.86 | ALDH1A1 (0.67) | ALDH1A1MAPTRECQLHTTNPSR1 | |
| SCHEMBL1843368 | 0.86 | MAPT (0.73) | ALDH1A1MAPTRECQLHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11568956-B2 | Methods for identifying inhibitors of amyloid protein aggregation | TREVENTIS CORPORATION (US) | 2023-01-31 | — | — | US | disclosed |
| US-20190050526-A1 | METHODS FOR IDENTIFYING INHIBITORS OF AMYLOID PROTEIN AGGREGATION | TREVENTIS CORPORATION (US) | 2019-02-14 | — | — | US | disclosed |
| US-20160283652-A1 | METHODS FOR IDENTIFYING INHIBITORS OF AMYLOID PROTEIN AGGREGATION | TREVENTIS CORPORATION (US) | 2016-09-29 | — | — | US | disclosed |
| CN-102170882-B | Compositions and methods of treating amyloid disease | TREVENTIS CORP | 2014-04-02 | — | — | CN | disclosed |
| US-8420640-B2 | Methods of treating amyloid disease using analogs of 1-(4-nitrophenyl) piperazine | TREVENTIS CORPORATION (US) | 2013-04-16 | — | — | US | disclosed |
| US-20110218200-A1 | METHODS OF TREATING AMYLOID DISEASE USING ANALOGS OF 1-(4-NITROPHENYL) PIPERAZINE | TREVENTIS CORPORATION | 2011-09-08 | — | — | US | disclosed |
| EP-2320897-A1 | COMPOSITIONS AND METHODS OF TREATING AMYLOID DISEASE | Treventis Corporation (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010025375-A1 | COMPOSITIONS AND METHODS OF TREATING AMYLOID DISEASE | TREVENTIS CORPORATION (US) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218200-A1 | METHODS OF TREATING AMYLOID DISEASE USING ANALOGS OF 1-(4-NITROPHENYL) PIPERAZINE | PSEN1, PSEN2, APP | ALDH1A1 1948/4885MAPT 10/4885RECQL 1123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.